Generation Bio Co. (GBIO)
Feb 9, 2026 - GBIO was delisted (reason: acquired by XOMA)
5.34
-0.40 (-6.97%)
Inactive · Last trade price on Feb 6, 2026
Company Description
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells.
It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity.
The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017.
Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Generation Bio Co.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jun 12, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Yalonda Howze |
Contact Details
Address: 301 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 655 7500 |
| Website | generationbio.com |
Stock Details
| Ticker Symbol | GBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 1733294 |
| CUSIP Number | 37148K209 |
| ISIN Number | US37148K2096 |
| Employer ID | 81-4301284 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yalonda Howze J.D. | Interim Chief Executive Officer and President |
| Antoinette Paone M.B.A., M.S. | Chief Operating Officer |
| Dr. Phillip Samayoa Ph.D. | Chief Scientific Officer |
| Dr. Mark D. Angelino Ph.D. | Co-Founder |
| Dr. Robert Kotin Ph.D. | Co-Founder |
| Kevin John Conway | Chief Financial Officer |
| Jasmin Tower | Chief Human Resources Officer |
| Caitlin Cooper M.B.A. | Senior Vice President and Head of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 9, 2026 | POS AM | Post-Effective amendments for registration statement |
| Feb 9, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 9, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 9, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 9, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 9, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 9, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 9, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 9, 2026 | 8-K | Current Report |
| Feb 9, 2026 | SC 14D9/A | Filing |